- Home
- DNA vs YMAB Comparison
DNA vs YMAB Comparison
Compare DNA & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNA
- YMAB
- Stock Information
- Founded
- DNA 2008
- YMAB 2015
- Country
- DNA United States
- YMAB United States
- Employees
- DNA N/A
- YMAB N/A
- Industry
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- DNA Health Care
- YMAB Health Care
- Exchange
- DNA Nasdaq
- YMAB Nasdaq
- Market Cap
- DNA 562.1M
- YMAB 482.4M
- IPO Year
- DNA N/A
- YMAB 2018
- Fundamental
- Price
- DNA $13.90
- YMAB $5.80
- Analyst Decision
- DNA Hold
- YMAB Strong Buy
- Analyst Count
- DNA 6
- YMAB 10
- Target Price
- DNA $37.80
- YMAB $21.10
- AVG Volume (30 Days)
- DNA 1.3M
- YMAB 439.0K
- Earning Date
- DNA 02-27-2025
- YMAB 02-27-2025
- Dividend Yield
- DNA N/A
- YMAB N/A
- EPS Growth
- DNA N/A
- YMAB N/A
- EPS
- DNA N/A
- YMAB N/A
- Revenue
- DNA $217,951,000.00
- YMAB $84,553,000.00
- Revenue This Year
- DNA N/A
- YMAB $6.26
- Revenue Next Year
- DNA N/A
- YMAB $19.43
- P/E Ratio
- DNA N/A
- YMAB N/A
- Revenue Growth
- DNA N/A
- YMAB N/A
- 52 Week Low
- DNA $5.26
- YMAB $5.71
- 52 Week High
- DNA $64.40
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- DNA 61.31
- YMAB 20.11
- Support Level
- DNA $11.85
- YMAB $5.93
- Resistance Level
- DNA $14.61
- YMAB $6.39
- Average True Range (ATR)
- DNA 1.25
- YMAB 0.39
- MACD
- DNA 0.14
- YMAB 0.10
- Stochastic Oscillator
- DNA 77.81
- YMAB 7.91
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.